Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 10/05/22
End: 01/31/26
Due: 01/31/27
Phase: N/A
Priority: Normal
Start: 02/20/21
End: 08/31/23
Due: 08/31/24
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer Patients | NCT06015126 | Yan Xue | user2@example.com | None | 2022-10-05 | 2026-01-31 | 2027-01-31 | - | - | 2025-07-14 |
| Efficacy and Safety of Inetetamab Plus Pyrotiniband and Capecitabine in HER2-positive Metastatic Breast Cancer Patients With or Without Brain Metastasis | NCT06015100 | Yan Xue | user2@example.com | None | 2021-02-20 | 2023-08-31 | 2024-08-31 | - | - | 2025-07-14 |